Free Trial

Arbutus Biopharma (ABUS) SEC Filings & 10K Form

Arbutus Biopharma logo
$3.64 +0.01 (+0.28%)
(As of 11/15/2024 ET)

Recent Arbutus Biopharma SEC Filings

DateFilerForm TypeView
11/15/2024
10:03 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
7:41 AM
Arbutus Biopharma (Subject)
Two Seas Capital LP (Filed by)
Form SC 13G/A
11/06/2024
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2024
7:26 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/11/2024
3:07 PM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/01/2024
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/10/2024
3:50 PM
Arbutus Biopharma (Subject)
MORGAN STANLEY (Filed by)
Form SC 13G
06/06/2024
10:16 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2024
5:00 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/28/2024
3:25 PM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/24/2024
3:07 PM
Arbutus Biopharma (Issuer)
Torti Frank (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2024
5:00 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/17/2024
8:03 AM
Arbutus Biopharma (Subject)
Whitefort Capital Management, LP (Filed by)
Form SC 13D/A
05/09/2024
7:00 AM
Arbutus Biopharma (Subject)
Whitefort Capital Management, LP (Filed by)
Form SC 13D
05/02/2024
3:32 PM
Arbutus Biopharma (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/02/2024
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
6:26 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/10/2024
3:05 PM
Arbutus Biopharma (Filer)
Form DEF 14A
04/10/2024
3:06 PM
Arbutus Biopharma (Filer)
Form DEFA14A
04/04/2024
7:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/29/2024
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/12/2024
8:41 AM
Arbutus Biopharma (Subject)
BlackRock Inc. (Filed by)
Form SC 13G/A
02/05/2024
6:54 PM
Arbutus Biopharma (Issuer)
McElhaugh Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2024
6:54 PM
Arbutus Biopharma (Issuer)
Sofia Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2024
6:54 PM
Arbutus Biopharma (Issuer)
HASTINGS DAVID C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2024
6:55 PM
Arbutus Biopharma (Issuer)
Sims Karen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2024
6:55 PM
Arbutus Biopharma (Issuer)
Naftzger J. Christopher (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2024
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/04/2024
3:09 PM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/21/2023
7:00 AM
Arbutus Biopharma (Subject)
Two Seas Capital LP (Filed by)
Form SC 13G
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ABUS) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners